Published online Apr 26, 2021. doi: 10.12998/wjcc.v9.i12.2739
Peer-review started: November 11, 2020
First decision: December 31, 2020
Revised: January 13, 2021
Accepted: February 24, 2021
Article in press: February 24, 2021
Published online: April 26, 2021
Processing time: 154 Days and 15.8 Hours
Superficial CD34-positive fibroblastic tumor (SCPFT) is a newly discovered mesenchymal tumor that is mainly composed of fibroblasts. Given the lack of established diagnostic criteria, SCPFT is associated with a high misdiagnosis rate
We are writing this paper to further describe the histopathological characteristics and genetic characteristics of this entity so that pathologists can more accurately diagnose the disease.
The main purpose of this study was to further elucidate the characteristics of SCPFT; its genetic characteristics are of great concern to pathologists.
We retrospectively analyzed the clinicopathological, immunohistochemical, and fluorescence in situ hybridization characteristics of four SCPFT patients treated at our institution.
In general, these tumors are mostly single well-defined nodules. Microscopically, the tumors were composed of irregular spindle to oval-shaped cells with eosinophilic and granular cytoplasm. A few scattered tumor cells were markedly polymorphic with hyperchromatic, abnormal, and pleomorphic nuclei that frequently displayed intranuclear pseudoinclusions. Hematoxylin–eosin staining of some tumors with interstitial mucoid degeneration was similar to that of mucinous fibroblastic sarcoma. Immunohistochemical staining showed that CD34 was strongly expressed in all cases, and approximately 60% of the tumors expressed CK locally (AE1/AE3). ALK and PDGFB gene rearrangements were analyzed in all four cases by fluorescence in situ hybridization. The four tumors were negative for ALK rearrangements, and PDGFB rearrangements were not detected.
Our findings may further contribute to the recognition of SCPFTs, including the clinical context in which they arise; it is important to avoid confusion with other pleomorphic soft tissue tumors, particularly neoplasms in the group of pleomorphic sarcomas, which are typically aggressive tumors, as that could lead to unnecessary overtreatment.
In follow-up work, more cases will be collected for comparative studies of the clinical and pathological aspects. An in-depth analysis will be conducted at the genetic level through second-generation sequencing to confirm the uniqueness of this entity and provide the basis for precise clinical treatment.